Jaguar Health (JAGX) Stock Price

Jaguar Health, Inc. generates revenue through the commercialization of gastrointestinal pharmaceuticals, primarily Mytesi for HIV/AIDS patients on antiretroviral therapy. The company markets Mytesi, Canalevia, Equilevia, Neonorm Calf, and Neonorm Foal, targeting both human prescription and animal health segments. Its subsidiary Napo Pharmaceuticals, Inc. develops plant-derived products from rainforest traditions, focusing on sustainable sourcing for global markets. Revenue streams are derived from direct sales to healthcare providers and veterinary suppliers in the human and animal gastrointestinal health sectors. The company's products serve distinct market segments: Mytesi addresses human prescription needs for HIV/AIDS-related diarrhea, while Canalevia, Equilevia, Neonorm Calf, and Neonorm Foal cater to veterinary use for horses, calves, and foals. Napo Pharmaceuticals, Inc. supports the development of rainforest-sourced gastrointestinal treatments, aligning with the company's focus on sustainable plant-based solutions. Sales are directed toward medical professionals and veterinary practitioners globally. Jaguar Health, Inc. monetizes its pharmaceutical portfolio through prescription drug sales and veterinary product distribution. Mytesi is the primary revenue driver for human gastrointestinal health, while animal health products like Neonorm Calf and Neonorm Foal target livestock and equine markets. The company's business model emphasizes sustainable plant-derived ingredients, leveraging traditional rainforest knowledge to differentiate its offerings in both human and animal health markets.